Elranatamab in R/R Multiple Myeloma

Clinical trial NCT06138275 · RECRUITING

Trial details

NCT number: NCT06138275
Sponsor: Massachusetts General Hospital
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Refractory Multiple Myeloma Relapse Multiple Myeloma Multiple Myeloma

Start date: 2024-03-08
Primary completion: 2026-08-01
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.